Bristol Myers (BMY) Squibb is expanding its existing strategic productivity initiative to include approximately $2B in additional annualized cost savings by the end of 2027. Under this expanded initiative, savings will be driven by changes in organizational design and efforts to enhance operational efficiency. These savings will be removed from our cost structure to contribute to a leaner, more efficient company while investing behind growth brands and promising areas of science.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers sees FY25 adjusted EPS $6.55-$6.85, consensus $6.92
- Options Volatility and Implied Earnings Moves Today, February 06, 2025
- Notable companies reporting before tomorrow’s open
- Bristol Myers Squibb call volume above normal and directionally bullish
- BMY Earnings Report this Week: Is It a Buy, Ahead of Earnings?